New York State Common Retirement Fund Purchases 3,199 Shares of La Jolla Pharmaceutical Company (LJPC)

New York State Common Retirement Fund grew its position in shares of La Jolla Pharmaceutical Company (NASDAQ:LJPC) by 21.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 18,300 shares of the biopharmaceutical company’s stock after purchasing an additional 3,199 shares during the quarter. New York State Common Retirement Fund owned approximately 0.08% of La Jolla Pharmaceutical worth $545,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the company. Emory University acquired a new stake in shares of La Jolla Pharmaceutical during the second quarter valued at about $1,410,000. Nationwide Fund Advisors boosted its stake in shares of La Jolla Pharmaceutical by 20.4% during the second quarter. Nationwide Fund Advisors now owns 9,952 shares of the biopharmaceutical company’s stock valued at $296,000 after purchasing an additional 1,688 shares in the last quarter. TIAA CREF Investment Management LLC boosted its stake in shares of La Jolla Pharmaceutical by 29.5% during the second quarter. TIAA CREF Investment Management LLC now owns 47,043 shares of the biopharmaceutical company’s stock valued at $1,400,000 after purchasing an additional 10,703 shares in the last quarter. Teachers Advisors LLC boosted its stake in shares of La Jolla Pharmaceutical by 21.5% during the second quarter. Teachers Advisors LLC now owns 30,859 shares of the biopharmaceutical company’s stock valued at $919,000 after purchasing an additional 5,469 shares in the last quarter. Finally, Alliancebernstein L.P. boosted its stake in shares of La Jolla Pharmaceutical by 34.6% during the second quarter. Alliancebernstein L.P. now owns 17,100 shares of the biopharmaceutical company’s stock valued at $509,000 after purchasing an additional 4,400 shares in the last quarter.

La Jolla Pharmaceutical Company (NASDAQ LJPC) opened at $34.88 on Friday. La Jolla Pharmaceutical Company has a 12 month low of $16.41 and a 12 month high of $39.28.

La Jolla Pharmaceutical (NASDAQ:LJPC) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported ($1.19) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.24) by $0.05. equities analysts anticipate that La Jolla Pharmaceutical Company will post -4.93 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “New York State Common Retirement Fund Purchases 3,199 Shares of La Jolla Pharmaceutical Company (LJPC)” was first published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://www.chaffeybreeze.com/2017/11/12/new-york-state-common-retirement-fund-purchases-3199-shares-of-la-jolla-pharmaceutical-company-ljpc.html.

A number of brokerages have recently commented on LJPC. Zacks Investment Research lowered La Jolla Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. Jefferies Group LLC reissued a “buy” rating and set a $40.00 price target on shares of La Jolla Pharmaceutical in a research note on Tuesday, October 3rd. J P Morgan Chase & Co began coverage on La Jolla Pharmaceutical in a research note on Wednesday, August 30th. They set an “overweight” rating and a $36.00 price target on the stock. BidaskClub raised La Jolla Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Wednesday, August 9th. Finally, Chardan Capital reissued a “buy” rating and set a $85.00 price target on shares of La Jolla Pharmaceutical in a research note on Tuesday, August 8th. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $52.00.

La Jolla Pharmaceutical Company Profile

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH).

Institutional Ownership by Quarter for La Jolla Pharmaceutical (NASDAQ:LJPC)

Receive News & Ratings for La Jolla Pharmaceutical Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply